High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center.

Publication/Presentation Date

1-1-2021

Abstract

OBJECTIVES: Prostate cancer incidence is increasing in the Middle East (ME); however, the data of stage at the diagnosis and treatment outcomes are lacking. In developed countries, the incidence of

METHODS: After Institutional Review Board approval, we identified the patients diagnosed with prostate adenocarcinoma and presented to a tertiary care center between January 2010 and July 2015. Clinical, demographic, and pathological characteristics were abstracted. Patients with advanced disease were stratified according to tumor volume based on definitions from practice changing clinical trials. Descriptive and Kaplan-Meier survival analysis was used.

RESULTS: A total of 559 patients were identified, with a median age at the diagnosis of 65 years and an age range of 39-94 years. Median prostate-specific antigen (PSA) at the presentation was 10 ng/ml, and almost a quarter of the men (23%) presented with metastatic disease. The most common site of metastasis was the bone (34/89, 38%). High-volume metastasis was present in 30.3%, 9%, and 5.2% of the cohort based on STAMPEDE, CHAARTED, and LATITUDE trial criteria, respectively.

CONCLUSION: This is the first report showing the high proportion of men from ME presenting with

Volume

13

Issue

4

First Page

418

Last Page

423

ISSN

0974-7796

Disciplines

Medicine and Health Sciences

PubMedID

34759656

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Share

COinS